NREP
NEW REPRESENTATIVE AT IB RECEIVED
25/05/2024
Voltar para busca
Dado oficial do USPTO
NEURAMEDY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
25/05/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
06/10/2021
Data de registro
25/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/04/2023
Última transação
08/07/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
KR
Examinador
GILBERT, REBECCA
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the gray stylized word "NEURAMEDY" with a blue circle design to the left. Inside the blue circle is a design of an "N" comprised of two separate white angular curved lines.
Titulares e representantes
Titulares
Neuramedy Co., Ltd.
Representantes
Cindy L. Caditz Davis Wright Tremaine LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for human purposes for the treatment of Central Nervous System (CNS) diseases; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; ophthalmic preparations; allergy medications; pharmaceutical preparations for diagnosis of Central Nervous System (CNS) diseases; pharmaceutical preparations and substances with analgesic properties; ethical medicinal preparations for the treatment of Central Nervous System (CNS) diseases; therapeutic drugs and therapeutic agents for treating Central Nervous System (CNS) diseases; pharmaceutical preparations for the treatment of Parkinson's disease; plant extracts for pharmaceutical purposes; medicated lozenges for pharmaceutical purposes; pharmaceutical preparations for use in dermatology; ferments for pharmaceutical purposes; pharmaceutical agents affecting sensory organs; drugs for medical purposes for the treatment of Central Nervous System (CNS) diseases; pharmaceutical preparations for the treatment of Central Nervous System (CNS) diseases
Classe 42
Research and development of vaccines and medicines; medical research in the field of crude drugs; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research services; medical and scientific researchclinical testing of medicines; pharmaceutical drug development services; consultancy pertaining to pharmacology; testing of pharmaceuticals; pharmaceutical product evaluation; medical laboratory services; scientific research services for medical purposes; scientific research in the field of medicine; scientific analysis and evaluation of medical product development; medical and pharmacological research services; scientific research in the fields of medicine/health and pharmacology; scientific research in the nature of conducting clinical trials for others; development of medical products
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/08/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/08/2023
FIMP
FINAL DISPOSITION PROCESSED
03/08/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/07/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
30/06/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/06/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/06/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/06/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/05/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
25/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
25/04/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/04/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/04/2023
GPNX
NOTIFICATION PROCESSED BY IB
07/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/02/2023
PUBO
PUBLISHED FOR OPPOSITION
07/02/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/01/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
05/01/2023
ALIE
ASSIGNED TO LIE
05/01/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/01/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
04/01/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/12/2022
RFNT
REFUSAL PROCESSED BY IB
23/08/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/08/2022
RFRR
REFUSAL PROCESSED BY MPU
02/08/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/07/2022
CNRT
NON-FINAL ACTION WRITTEN
12/07/2022
DOCK
ASSIGNED TO EXAMINER
12/07/2022
MAFR
APPLICATION FILING RECEIPT MAILED
16/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NEURAMEDY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.